Pharmafile Logo
Pharmafocus logo
Advanced Search

Kisqali

Showing 11 posts of 11 posts found.

Novartis’ Kisqali delays need for chemo by over 4 years in post-menopausal HR+HER2- metastatic breast cancer

December 9, 2020
Research and Development Kisqali, Novartis, breast cancer

Novartis has lifted the curtain on updated Phase 3 data for Kisqali (ribociclib) in the treatment of hormone receptor positive, …

News

Novartis’ Kisqali approved for NHS Scotland in most common advanced breast cancer

November 12, 2019
Manufacturing and Production, Sales and Marketing Cancer, Kisqali, NHS, Novartis, Scotland, breast cancer, pharma

NHS patients in Scotland will soon be able to access Novartis’ CDK4/6 inhibitor Kisqali (ribociclib) after the Scottish Medicines Consortium …

News
novartis_outside_1

Novartis’ Kisqali reinforces overall survival benefit in postmenopausal HR+/HER2- breast cancer

August 1, 2019
Research and Development Cancer, Kisqali, Novartis, breast cancer, pharma

New Phase 3 evidence has emerged on the efficacy of Novartis’ Kisqali (ribociclib) in combination with AstraZeneca’s Faslodex (fulvestrant) in …

News

NICE greenlights Novartis Kisqali combo in HR+/HER2- advanced breast cancer

July 17, 2019
Manufacturing and Production, Medical Communications, Research and Development Cancer, Kisqali, NICE, Novartis, UK, breast cancer, pharma

Novartis’ Kisqali (ribociclib) has secured recommendation from NICE in combination with fulvestrant, meaning the cyclin-dependent kinase 4 and 6 (CDK4/6) …

News

Novartis’ Kisqali combo boosts survival in HR+/HER2- advanced breast cancer

June 3, 2019
Research and Development, Sales and Marketing Cancer, Kisqali, Novartis, breast cancer, pharma

Novartis took the opportunity at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting to reveal new Phase 3 …

News
novartis_window

Novartis’ Kisqali combo rejected by NICE for advanced breast cancer

April 11, 2019
Sales and Marketing Kisqali, NHS, NICE, Novartis, pharma

Novartis’ Kisqali (ribociclib) has been rejected for use on the NHS by NICE for the treatment of advanced breast cancer, …

News
Novartis image

Novartis’ Kisqali gains breakthrough status in premenopausal breast cancer

January 3, 2018
Research and Development, Sales and Marketing Kisqali, Novartis, biotech, drugs, pharma, pharmaceutical

Novartis has received a major boost in its efforts to broaden use of its CDK4/6 inhibitor, by receiving a breakthrough …

News
novartislr

Novartis Kisqali improves PFS in younger women

December 7, 2017
Research and Development Kisqali, Novartis, biotech, drugs, pharma, pharmaceutical

A Phase 3 trial looking at the use of Kisqali (ribociclib) to treat premenopausal or perimenopausal women with hormone-receptor positive, …

News

NICE approves Novartis and Pfizer’s rival breast cancer drugs

November 16, 2017
Sales and Marketing Kisqali, Novartis, Pfizer, biotech, drugs, ibrance, pharma, pharmaceutical

NICE has announced that it has given the nod to two new treatments for breast cancer with the approval of …

News
novartis_outside_1

Novartis’ Kisqali smashes Phase 3 primary endpoint in breast cancer for second time

November 8, 2017
Research and Development Cancer, Kisqali, Novartis, breast cancer, pharma

Novartis has revealed that its immunotherapy drug Kisqali (ribociclib) met its primary endpoint of progression-free survival in its second Phase …

News

Novartis secures first-line FDA approval in breast cancer indication

March 14, 2017
Manufacturing and Production, Sales and Marketing Kisqali, Novartis, breast cancer

The FDA has approved Kisqali (ribociclib) in combination with letrozole for the first-line treatment of postmenopausal women with hormone receptor …

News

Latest content

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China

June 28, 2024

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024

Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA

June 27, 2024

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024